Related Experiment Video
Updated: Aug 9, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Interleukin-6 in rheumatoid arthritis
1Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan. norihiro@fbs.osaka-u.ac.jp
Current Opinion in Rheumatology
|April 4, 2006
Summary
Interleukin-6 (IL-6) plays a key role in rheumatoid arthritis. Blocking IL-6 with tocilizumab offers a promising second-generation therapy for this autoimmune disease.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Cytokines are implicated in autoimmune inflammatory diseases like rheumatoid arthritis (RA).
- Existing therapies targeting tumor necrosis factor-alpha and interleukin-1 for RA show limitations.
- Interleukin-6 (IL-6) is a significant cytokine in RA pathogenesis, presenting a therapeutic target.
Purpose of the Study:
- To review the pathological role of IL-6 in rheumatoid arthritis.
- To evaluate the current status and efficacy of anti-IL-6 therapy for RA.
Main Methods:
- Review of clinical trials and studies on IL-6 and its blockade.
- Focus on tocilizumab, a monoclonal antibody targeting the IL-6 receptor.
Main Results:
- Clinical studies confirm the pathological significance of IL-6 in RA.
- Tocilizumab has demonstrated safety and efficacy in clinical trials for RA.
- Tocilizumab is also effective in other autoimmune diseases like juvenile idiopathic arthritis and Crohn's disease.
Conclusions:
- IL-6 blockade represents a promising therapeutic strategy for rheumatoid arthritis.
- Tocilizumab, as a second-generation anti-cytokine therapy, shows significant potential for RA treatment.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...